Cargando…

Indication and efficacy of PEIT in the management of secondary hyperparathyroidism

Control of secondary hyperparathyroidism (SHPT) using active vitamin D analogues becomes difficult in advanced SHPT, because the enlarged parathyroid glands (PTGs) are resistant to medical therapy. Percutaneous ethanol injection therapy (PEIT) has been widely used in Japan since the 1990s as a surgi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Koiwa, Fumihiko, Hasegawa, Takeshi, Tanaka, Reika, Kakuta, Takatoshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2008
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4421135/ https://www.ncbi.nlm.nih.gov/pubmed/25983965 http://dx.doi.org/10.1093/ndtplus/sfn081

Ejemplares similares

Long-term prognosis of parathyroid function in chronic dialysis patients after PEIT—a single-centre trial
por: Tanaka, Reika, et al.
Publicado: (2008)

Percutaneous ethanol injection therapy for advanced renal hyperparathyroidism in Japan: 2004 survey by the Japanese Society for Parathyroid Intervention
por: Kakuta, Takatoshi, et al.
Publicado: (2008)

Efficacy of Evocalcet in Previously Cinacalcet-Treated Secondary Hyperparathyroidism Patients
por: Koiwa, Fumihiko, et al.
Publicado: (2021)

Reversed whole PTH/intact PTH ratio as an indicator of marked parathyroid enlargement: five case studies and a literature review
por: Komaba, Hirotaka, et al.
Publicado: (2008)

First-in-Patient Phase I/II Study of Upacicalcet in Japanese Patients with Secondary Hyperparathyroidism Undergoing Hemodialysis: Pharmacokinetic and Pharmacodynamic Properties
por: Kazama, Junichiro James, et al.
Publicado: (2022)

Phase 2 study of upacicalcet in Japanese haemodialysis patients with secondary hyperparathyroidism: an intraindividual dose-adjustment study
por: Inaguma, Daijo, et al.
Publicado: (2023)

Parathyroid hormone-producing cells exist in adipose tissues surrounding the parathyroid glands in hemodialysis patients with secondary hyperparathyroidism
por: Kakuta, Takatoshi, et al.
Publicado: (2020)

New clinical guidelines for selective direct injection therapy of the parathyroid glands in chronic dialysis patients
por: Onoda, Noritaka, et al.
Publicado: (2008)

Surgical Management of Secondary Hyperparathyroidism
por: Steinl, Gabrielle K., et al.
Publicado: (2020)

Method comparison of Particle Enhanced Immunoturbidimetry (PEIT) with High Performance Liquid Chromatography (HPLC) for glycated hemoglobin (HbA1c) analysis
por: Dildar, Shabnam, et al.
Publicado: (2021)

The impact of secondary hyperparathyroidism on the efficacy of antiresorptive therapy
por: Kincse, Gyöngyvér, et al.
Publicado: (2012)

Efficacy and safety of oral doxercalciferol in the management of secondary hyperparathyroidism in chronic kidney disease stage 4
por: Dheerendra, P. C., et al.
Publicado: (2013)

Hemodialysis patients’ preferences for the management of secondary hyperparathyroidism
por: Hauber, Brett, et al.
Publicado: (2017)

Clinical prediction models for progression of chronic kidney disease to end-stage kidney failure under pre-dialysis nephrology care: results from the Chronic Kidney Disease Japan Cohort Study
por: Hasegawa, Takeshi, et al.
Publicado: (2018)

Treatment for secondary hyperparathyroidism focusing on parathyroidectomy
por: Hiramitsu, Takahisa, et al.
Publicado: (2023)

Association between long-term efficacy of cinacalcet and parathyroid gland volume in haemodialysis patients with secondary hyperparathyroidism
por: Tanaka, Motoko, et al.
Publicado: (2008)

PTH-dependence of the effectiveness of cinacalcet in hemodialysis patients with secondary hyperparathyroidism
por: Akizawa, Tadao, et al.
Publicado: (2016)

Dose–response efficacy and safety of PA21 in Japanese hemodialysis patients with hyperphosphatemia: a randomized, placebo-controlled, double-blind, Phase II study
por: Koiwa, Fumihiko, et al.
Publicado: (2016)

Efficacy of intraoperative parathyroid hormone monitoring to predict success of parathyroidectomy for secondary hyperparathyroidism
por: Kim, Woo Young, et al.
Publicado: (2012)

One-year safety and efficacy of intravenous etelcalcetide in patients on hemodialysis with secondary hyperparathyroidism
por: Bushinsky, David A, et al.
Publicado: (2019)

Management of severe hypercalcaemia secondary to primary hyperparathyroidism: The efficacy of saline hydration, furosemide, and zoledronic acid
por: Oueslati, Ibtissem, et al.
Publicado: (2022)

Secondary Hyperparathyroidism in Chronic Kidney Disease: Pathophysiology and Management
por: Habas, Elmukhtar, et al.
Publicado: (2021)

Management of pre-renal transplant secondary hyperparathyroidism: parathyroidectomy versus cinacalcet
por: Elhadedy, Muhammed Ahmed, et al.
Publicado: (2023)

The association of the difference in hemoglobin levels before and after hemodialysis with the risk of 1-year mortality in patients undergoing hemodialysis. Results from a nationwide cohort study of the Japanese Renal Data Registry
por: Nishiwaki, Hiroki, et al.
Publicado: (2019)

Bone microarchitecture in patients undergoing parathyroidectomy for management of secondary hyperparathyroidism
por: Ruderman, Irene, et al.
Publicado: (2020)

Current status of parathyroidectomy for secondary hyperparathyroidism in Japan
por: Tominaga, Yoshihiro
Publicado: (2008)

A New Paradigm for the Treatment of Secondary Hyperparathyroidism
por: de Francisco, Angel L. M., et al.
Publicado: (2008)

Serum nuclear factor IB as a novel and noninvasive indicator in the diagnosis of secondary hyperparathyroidism
por: Yu, Jian’gen, et al.
Publicado: (2021)

Racial Differences in Secondary Hyperparathyroidism
por: Kato, Akihiko
Publicado: (2013)

Skeletal findings in secondary hyperparathyroidism
por: Koratala, Abhilash, et al.
Publicado: (2017)

Bradycardia secondary to primary hyperparathyroidism
por: Liu, Fei, et al.
Publicado: (2019)

Association between serum Na–Cl level and renal function decline in chronic kidney disease: results from the chronic kidney disease Japan cohort (CKD-JAC) study
por: Maruta, Yuichi, et al.
Publicado: (2018)

Efficacy of microwave ablation for severe secondary hyperparathyroidism in subjects undergoing hemodialysis
por: Diao, Zongli, et al.
Publicado: (2016)

Reoperation for persistent or recurrent secondary hyperparathyroidism. Surgical treatment of renal hyperparathyroidism
por: Abruzzo, Alida, et al.
Publicado: (2017)

Efficacy and safety of radiofrequency ablation for primary and secondary hyperparathyroidism: a retrospective study
por: Qiu, Xinguang, et al.
Publicado: (2023)

Clinical Outcomes in Secondary Hyperparathyroidism and the Potential Role of Calcimimetics
por: Cunningham, John, et al.
Publicado: (2008)

Secondary Hyperparathyroidism Disease Stabilization Following Calcimimetic Therapy
por: Frazão, João, et al.
Publicado: (2008)

The Role of the Calcium-Sensing Receptor in the Pathophysiology of Secondary Hyperparathyroidism
por: Riccardi, Daniela, et al.
Publicado: (2008)

Pharmacodynamics of evocalcet for secondary hyperparathyroidism in Japanese hemodialysis patients
por: Shigematsu, Takashi, et al.
Publicado: (2018)

Efficacy and Safety of Evocalcet Evaluated by Dialysate Calcium Concentration in Patients with Secondary Hyperparathyroidism Undergoing Hemodialysis
por: Shigematsu, Takashi, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_2c6a12dq1birdb1ue20kul30jt